tbuckley/cabot-search huggingface dataset:
A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
Authors: Karen A. Autio, Jorge A. Garcia, Ajjai Shivaram Alva, Lowell L. Hart, Matthew I. Milowsky, Edwin M. Posadas, Charles J. Ryan, Jason Mark Summa, Hagop Youssoufian, Howard I. Scher, Robert Dreicer
Journal: Journal of Clinical Oncology (2016)

233 Background: BIND-014 is a novel PSMA-targeted Accurin (polymeric nanoparticle) that contains docetaxel (D). BIND-014 is anticipated to improve the therapeutic index of D by increasing its intratumoral concentration and duration of exposure. In a phase 1 study, BIND-014 was generally well-tolerated and displayed anti-tumor effects, including in two patients with chemotherapy-naïve mCRPC. Methods: A phase 2 study was conducted of BIND-014 administered by a 60-min IV infusion at 60 mg/m² on day 1 of a 21-day cycle in combination with 5 mg of prednisone twice per day to patients with chemotherapy-naïve mCRPC. Prior treatment included abiraterone acetate (AA, 48%), enzalutamide (E, 12%) or both (14%). Of these 31 patients 19% progressed within ≤ 6 months on prior AA and/or E. The primary endpoint was radiographic progression-free survival (rPFS) using PCWG2 for bone and RECIST v1.1. Other endpoints included prostate specific antigen (PSA) and circulating tumor cell count (CTC) conversions, objective response rate (ORR), and overall survival (OS). Results: Forty-two patients were enrolled and received a median of 6 doses (range 1 – 21). Median rPFS was 7.1 months (95% CI: 2.6 – 9.9) with 4 patients (10%) censored. PSA response ( ≥ 50% reduction from baseline) was observed in 12 of 40 patients (30%). CTC conversions (from ≥ 5 CTCs/7.5 mL of blood at baseline to &lt; 5 CTCs) occurred in 13 of 26 patients (50%). ORR was 32% with 3 confirmed responses (1 complete response and 2 partial responses) and 3 unconfirmed responses out of 19 patients with measurable disease. Estimated median OS was 13.4 months (95% CI: 9.9 – 18.6) with 14 patients (33%) censored. The most common hematological treatment-related adverse events (TRAEs) observed were lymphopenia (26%), and anemia (19%).Fatigue (69%), nausea (55%), diarrhea (45%), dyspnea (36%), and neuropathy (33%) were the most common non-hematological TRAEs. The most common TRAEs were generally grade 1 and 2. Conclusions: BIND-014 administered at 60 mg/m² on day 1 of a 21-day cycle is clinically active and well-tolerated when administered to patients with chemotherapy-naïve mCRPC including those with prior AA and/or E. Clinical trial information: NCT01812746.
Authors’ reply to Kole
Authors: Ian E Haines, Richard J Ablin, George L Gabor Miklos
Journal: BMJ (2016)

We thank Kole for his response to our article calling for release of data underpinning Public Health England’s (PHE) advice to GPs and men over 50 on PSA screening.1 2 He notes PHE’s emphasis on current uncertainty and why this data release is vital.

PHE’s first point, that “you are more likely to die of prostate cancer and/or to …
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Authors: Vindi Jurinovic, Robert Kridel, Annette M. Staiger, Monika Szczepanowski, Heike Horn, Martin H. Dreyling, Andreas Rosenwald, German Ott, Wolfram Klapper, Andrew D. Zelenetz, Paul M. Barr, Jonathan W. Friedberg, Stephen Ansell, Laurie H. Sehn, Joseph M. Connors, Randy D. Gascoyne, Wolfgang Hiddemann, Michael Unterhalt, David M. Weinstock, Oliver Weigert
Journal: Blood (2016)
Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae : an observational study
Authors: Dilrini De Silva, Joanna Peters, Kevin Cole, Michelle J Cole, Fiona Cresswell, Gillian Dean, Jayshree Dave, Daniel Rh Thomas, Kirsty Foster, Alison Waldram, Daniel J Wilson, Xavier Didelot, Yonatan H Grad, Derrick W Crook, Tim E A Peto, A Sarah Walker, John Paul, David W Eyre
Journal: The Lancet Infectious Diseases (2016)
Reply to Sławomir Poletajew, Piotr Radziszewski, Juan Palou’s Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046–52
Authors: Tom J.H. Arends, J. Alfred Witjes
Journal: European Urology (2016)
Correlation of SUV-Derived Indices With Tumoral Aggressiveness of Gliomas in Static 18F-FDOPA PET
Authors: Lucile Janvier, Pierre Olivier, Marie Blonski, Olivier Morel, Jean-Michel Vignaud, Gilles Karcher, Luc Taillandier, Antoine Verger
Journal: Clinical Nuclear Medicine (2015)

Glioma grading is necessary for prognostic evaluation and optimal treatment decisions. The aims of this study were to establish whether a correlation between F-FDOPA uptake with tumor grade was observed and to determine which of the SUV-derived indices was the best correlated.Thirty-one patients were retrospectively included (mean [SD] age, 36.8 [12.1] years) including 21 proven low-grade tumors due to histology, imaging, and clinical follow-up and 10 histologically proven high-grade tumors. Static PET acquisitions were postreconstructed between the 10th and 30th minute after injection of F-FDOPA. Regions of interest of 20 mm were applied to tumors, and isocontoured volumes were defined at levels of 50% and 80% of the peak intensity voxel. Background was quantified with 30-mm-diameter regions of interest on contralateral striatum and centrum semioval. Tumoral uptake was evaluated with the following SUV-derived indices: SUVmax, SUVmean, SUVmax, and SUVmean of isocontoured volume, tumor/striatum ratio (T/S), and tumor/normal brain ratio (T/N).All the SUV-derived indices tested were significantly correlated with tumor grade, considering low-grade and high-grade groups (P < 0.05), except for the SUVmean 50%. The 2 best-correlated indices were SUVmean T/N and SUVmean T/S, with correlation coefficients of 0.561 and 0.522, respectively. Receiver operating characteristic analysis defined optimal thresholds of 1.33 and 1 for sensitivity and specificity of 71% and 100% and 67% and 100%, respectively.F-FDOPA PET SUV-derived indices are routinely available information that enables accurate discrimination of low-grade and high-grade gliomas. The best-correlated indices were SUVmean T/N and SUVmean T/S with thresholds of 1.33 and 1.
Proliferation of Coronary Adventitial Vasa Vasorum in Patients With Spontaneous Coronary Artery Dissection
Authors: Taek-Geun Kwon, Rajiv Gulati, Yasushi Matsuzawa, Tatsuo Aoki, Raviteja R. Guddeti, Joerg Herrmann, Ryan J. Lennon, Erik L. Ritman, Lilach O. Lerman, Amir Lerman
Journal: JACC. Cardiovascular imaging (2016)
Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group
Authors: E Manara, G Basso, M Zampini, B Buldini, C Tregnago, R Rondelli, R Masetti, V Bisio, M Frison, K Polato, G Cazzaniga, G Menna, F Fagioli, P Merli, A Biondi, A Pession, F Locatelli, M Pigazzi
Journal: Leukemia (2016)
Case 7-1969
Authors: C. Miller Fisher, Benjamin Castleman
Journal: New England Journal of Medicine (1969)

Presentation of CaseA fifty-six-year-old woman was admitted to the hospital because of a cough, fever and pain in the chest.She had begun to imbibe alcohol heavily at the time of her husband's death five years previously and increased her intake during the year before entry. Nine months before admission there was the onset of agitation and a progressively severe cough with hemoptysis. On admission to another hospital the diagnosis of right-lower-lobe pneumonia was made; she was discharged a week later. During the six months before entry she was anorectic, with a loss of 40 pounds in weight. Three . . .
The medium and the message: development of videotapes for teaching psychiatry
Authors: N C Roeske
Journal: American Journal of Psychiatry (1979)

The author examines the issues surrounding the development and use of videotapes to teach psychiatry. She describes the special capabilities of videotaped material as well as how videotapes are produced; the structure of videotapes that use feedback techniques; the different ways medical students, psychiatric students, and experienced clinicians respond to videotapes; the special problems involved with teaching nonpsychiatric medical students about psychiatry; and the use of videotaped materials for patients and the public. She concludes that the use of videotapes to teach psychiatry, especially to teach the public, is an important area for development by psychiatrists.
The effects of particulate air pollution on hospital admissions for cardiac diseases in potentially sensitive subgroups. a multicity case-crossover analysis.
Authors: P Colais, A Faustini, M Stafoggia, G Berti, L Bisanti, E Cadum, M Serinelli, L Simonato, M Vigotti, F Forastiere
Journal: Environmental Health Perspectives (2011)

Backgrounds and aims. Several studies have shown that particulate air pollution with aerodynamic diameter less than 10 micrometers (PM10) is associated with increased risk of hospital admissions fo...
SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation
Authors: Pinelopi Anagnostopoulou, Brigitte Riederer, Julia Duerr, Sven Michel, Aristea Binia, Raman Agrawal, Xuemei Liu, Katrin Kalitzki, Fang Xiao, Mingmin Chen, Jolanthe Schatterny, Dorothee Hartmann, Thomas Thum, Michael Kabesch, Manoocher Soleimani, Ursula Seidler, Marcus A. Mall
Journal: Journal of Clinical Investigation (2012)

Asthma is a chronic condition with unknown pathogenesis, and recent evidence suggests that enhanced airway epithelial chloride (Cl-) secretion plays a role in the disease. However, the molecular mechanism underlying Cl- secretion and its relevance in asthma pathophysiology remain unknown. To determine the role of the solute carrier family 26, member 9 (SLC26A9) Cl- channel in asthma, we induced Th2-mediated inflammation via IL-13 treatment in wild-type and Slc26a9-deficient mice and compared the effects on airway ion transport, morphology, and mucus content. We found that IL-13 treatment increased Cl- secretion in the airways of wild-type but not Slc26a9-deficient mice. While IL-13-induced mucus overproduction was similar in both strains, treated Slc26a9-deficient mice exhibited airway mucus obstruction, which did not occur in wild-type controls. In a study involving healthy children and asthmatics, a polymorphism in the 3' UTR of SLC26A9 that reduced protein expression in vitro was associated with asthma. Our data demonstrate that the SLC26A9 Cl- channel is activated in airway inflammation and suggest that SLC26A9-mediated Cl- secretion is essential for preventing airway obstruction in allergic airway disease. These results indicate that SLC26A9 may serve as a therapeutic target for airway diseases associated with mucus plugging.
Biological Activity of the Agent of Chicken Tumor I (Rous) in Citrate Buffers of Vaeious Molar Concentrations
Authors: W. Ray Bryan, Mary E. Maver, John B. Moloney, Dorothy Calnan, Carl L. White, Marguerite T. Wood
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Biological Activity of the Agent of Chicken Tumor I (Rous) in Citrate Buffers of Vaeious Molar Concentrations Get access W. Ray Bryan, W. Ray Bryan Search for other works by this author on: Oxford Academic PubMed Google Scholar Mary E. Maver, Mary E. Maver Search for other works by this author on: Oxford Academic PubMed Google Scholar John B. Moloney, John B. Moloney Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy Calnan, Dorothy Calnan Search for other works by this author on: Oxford Academic PubMed Google Scholar Carl L. White, Carl L. White Search for other works by this author on: Oxford Academic PubMed Google Scholar Marguerite T. Wood Marguerite T. Wood National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 5, April 1951, Pages 929–937, https://doi.org/10.1093/jnci/11.5.929 Published: 01 April 1951 Article history Received: 13 November 1950 Published: 01 April 1951
Incantation
Authors: Janet M. Torpy
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Simultaneous Occurrence of Neonatal Alloimmune Thrombocytopenia and Neutropenia Associated with Multiple Maternal Antibodies
Authors: Leandra Christina Nogueira-Silva, Samira Ali Abbas, Larissa Barbosa Lopes, Akemi Kuroda Chiba, Alessandra Kuniyoshi, Amélia Miyashiro dos Santos, Carlos Chiattone, Dante Mario Langhi, Elyse Moritz, Jose Orlando Bordin
Journal: Blood (2014)
UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.
Authors: Paul D. Nathan, Piers Gaunt, Keith Wheatley, Sarah Jane Bowden, Joshua Savage, Guy Faust, Jenny Nobes, Andrew Goodman, Diana Ritchie, Satish Kumar, Elizabeth R. Plummer, James E Lester, Christian H.H Ottensmeier, Vanessa Potter, Urmila Barthakur, Paul Lorigan, Ernie Marshall, James M. G. Larkin, Jeremy Marsden, Neil Matthew Steven
Journal: Journal of Clinical Oncology (2016)

9542 Background: The clinical activity of pazopanib, a multi-targeted tyrosine kinase inhibitor, was evaluated in metastatic Merkel Cell Carcinoma (MCC) following a case report demonstrating benefit in a phase II clinical trial. Methods: Patients with histologically confirmed unresectable metastatic MCC received pazopanib at a starting dose of 800mg or 600mg daily, as clinically indicated, following written informed consent. Chemotherapy pre-treated or naïve patients were eligible. This was a single arm, multi-center, UK, phase II trial using a Simon two-stage minimax design (p0 = 0.05, p1 = 0.20, alpha = 0.15, power = 90%). The primary outcome was clinical response rate measured by RECIST. In order to progress to the second stage, 1 responder was required in the first 19 patients, with; 3 or more responders in 25 patients required to confirm adequate activity for further clinical investigation. Results: Seventeen patients with histologically proven MCC were recruited between Jan-13 and Jan-16, when the trial was stopped as the primary objective of at least 3 responses was met and accrual was slow in this rare disease. The median age was 73 years (range 56 to 90). The median duration of treatment with pazopanib was 8.0 weeks (range 1.3 to 38.4). Patients discontinued treatment due to toxicity (2) and progression (13); 2 patients are still on treatment. At the time of reporting, 16/17 patients were evaluable: 3/16 partial responses were observed (response rate; 19%, lower 85% Wilsons confidence interval; 9%); a further 6 patients had SD with clinical benefit therefore seen in 9/16 (56%). Median progression-free survival time was 3.2 months (95% CI 1.4, 5.2) and median overall survival time was 6.4 months (95% CI 3.9, 13.2). Adverse events were comparable to those previously observed in trials in soft tissue sarcoma and renal cell carcinoma with pazopanib. Conclusions: Pazopanib has clinical activity in advanced MCC and warrants further investigation in this rare and poor prognosis cancer. Funded by Cancer Research UK (CRUK/11/015) with free drug and an educational grant from GlaxoSmithKline/Novartis. Clinical trial information: 10125877.
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes
Authors: Kamel Mohammedi, Mark Woodward, Sophia Zoungas, Qiang Li, Stephen Harrap, Anushka Patel, Michel Marre, John Chalmers
Journal: Diabetes Care (2016)

OBJECTIVE The burden of vascular diseases remains substantial in patients with type 2 diabetes, requiring identification of further risk markers. We tested the absence of dorsalis pedis and posterior tibial pulses as predictors of major macrovascular and microvascular events, death, and cognitive decline in this population. RESEARCH DESIGN AND METHODS Data were derived from 11,120 patients with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) study. Absent peripheral pulses at baseline were defined as absence of at least one dorsalis pedis or posterior tibial pulse. RESULTS Absent compared with present peripheral pulses (n = 2,218) were associated with increased 5-year risks for major macrovascular events (hazard ratio 1.47 [95% CI 1.28–1.69], P &amp;lt; 0.0001), myocardial infarction (1.45 [1.13–1.87], P = 0.003), stroke (1.57 [1.23–2.00], P = 0.0003), cardiovascular death (1.61 [1.33–1.95], P &amp;lt; 0.0001), heart failure (1.49 [1.21–1.84], P = 0.0002), all-cause mortality (1.48 [1.29–1.71], P &amp;lt; 0.0001), major microvascular events (1.17 [1.00–1.36], P = 0.04), nephropathy (1.24 [1.00–1.54], P = 0.04), end-stage renal disease or renal death (2.04 [1.12–3.70], P = 0.02), and peripheral neuropathy (1.13 [1.05–1.21], P = 0.0008) after multiple adjustment. Participants with absent dorsalis pedis or posterior tibial pulses had comparable hazard ratios. Risks increased proportionally with the number of absent peripheral pulses, with the highest risks observed in patients with three or four absent pulses. Every additional absent pulse increases the risk of all outcomes. CONCLUSIONS Absent dorsalis pedis and/or posterior tibial pulses are independent predictors of major vascular outcomes in patients with type 2 diabetes. These simple clinical indicators should be used to improve risk stratification and treatment of these patients.
Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL.
Authors: Kirk R. Schultz, Alexander Aledo, W. Paul Bowman, William Slayton, Harland Sather, Cheryl L. Willman, Julie M. Gastier-Foster, Nyla A. Heerema, Andrew J. Carroll, Michael J. Borowitz, Naomi Winick, Stephen P. Hunger, William L. Carroll
Journal: Blood (2006)
Using Canadian administrative data to evaluate primary and oncology care of breast cancer patients post-treatment: Subset of the CanIMPACT Study.
Authors: Mary L McBride, Patti Groome, Donna Turner, Margaret Jorgensen, Cynthia Kendell, Geoff Porter, Li Jiang, Monika Krzyzanowska, Aisha Lofters, Rahim Moineddin, Eva Grunfeld, Marcy Winget
Journal: Journal of Clinical Oncology (2016)

5 Background: CanIMPACT is a multi-provincial Canadian research team funded to identify and address key issues faced by cancer patients and providers at the intersection of primary and specialist oncology care. Canada has national healthcare standards, but provincial/territorial healthcare delivery systems. One facet will use administrative data from the population-based, publicly-funded healthcare system to evaluate issues during pre-diagnosis, treatment, and post-treatment survivorship for breast cancer patients. For the survivorship phase, we aim to conduct the following analyses and compare across provinces: 1) Utilization of physician services overall and by specialty, including oncologists, non-oncology specialists, and primary care; 2) Assessment of adherence to ASCO and Canadian follow-up guideline for breast cancer care, use of surveillance breast imaging, and metastatic investigations; 3) Assessment of adherence to recommended care of chronic illness and preventive care; 4) Quantification of the cost of follow-up overall and by specialty; 5) Comparison of inter- and intra-provincial variation for all outcomes by health administrative region and for vulnerable groups (age ≥ 75 at diagnosis, northern/rural/remote, low income, immigrants), and examine the effect of continuity of primary care and chronic disease on post-treatment care. Methods: Patients will be identified from provincial cancer registries and linked to data extracted from: outpatient physician service claims, hospital inpatient and outpatient data, and cancer facility medical records. Results: Participating provinces have finalized the core questions and detailed protocols, and assessed data comparability. They are in the process of obtaining the required ethics and data access approvals, and data acquisition for processing and analysis. Conclusions: Results will address existing information gaps that can be used to improve transition and care across the cancer care trajectory. Importantly, results will be combined with those of a CanIMPACT qualitative study to inform design of a pragmatic randomized trial focused on improving coordination and quality of care.